A target peak in a blank following a peptide standard is not evidence that the blank contains a new biological signal. Material from the preceding injection may remain in the autosampler, flow path or column. A useful carryover investigation asks where the residual signal originates and how much remains in subsequent blanks under the assay’s actual injection sequence.
What a neuropeptide Y experiment measured
In a published troubleshooting study, researchers injected 1 µL of 1 µM neuropeptide Y (NPY) into an LC–Orbitrap system and measured the NPY peak in subsequent blank runs. They defined carryover as the blank-peak abundance divided by abundance in the most recent NPY sample. The first blank was 4.05% of the preceding 1 µM sample. The same paper reports 0.36% and 0.47% for 5 and 10 µM NPY standards, respectively, under its tested conditions. A smaller percentage after a higher-concentration injection does not mean less absolute residue; the denominator changed. [1, Results and Discussion, Table 1]
| NPY standard, 1 µL injection | First-blank carryover ratio in study | Interpretation boundary |
|---|---|---|
| 1 µM | 4.05% | Ratio to that preceding standard’s signal |
| 5 µM | 0.36% | Different denominator and possibly different absolute residue |
| 10 µM | 0.47% | Assay-specific ratio, not a universal acceptance limit |
The investigators then changed parts of the flow path systematically. An experiment avoiding use of the sample needle during a blank reduced the 1 µM carryover estimate from 4.05% to 3.05%. Further comparisons without the column and after replacing needle and high-pressure valve seals implicated more than one surface. In the paper’s optimized configuration, which included seal replacement and removal of the guard column, the first blank was 2.15% and later blanks were below 0.9%. The 2.15% result cannot be attributed to seal replacement alone. These interventions locate contributions in that instrument; they do not provide a cleaning recipe for every LC–MS platform. [1, “Strategy for identifying carry-over sites,” Experiments 1–3 and Table 4]
A controlled troubleshooting sequence
Run a blank after a defined high standard and record the target’s retention time, mass/transition and signal. Repeat enough blanks to see whether signal decays; do not assume one blank clears it. Check a blank delivered without the normal sample path, where the instrument permits, to separate an ion-source or solvent background from the LC path. Change one component or wash condition at a time: needle path, valve or seal, tubing, guard column and analytical column. Document the same injected mass, blank timing, gradient and integration rule in each comparison.
Carryover and surface adsorption are related but answer different questions. Adsorption may lower signal in the current sample; later desorption can raise signal in the next blank. A blank can also be contaminated during preparation, so include independently prepared solvent and matrix blanks. Define a method-specific acceptance criterion relative to the lower limit of quantification and intended sample sequence; do not adopt the paper’s 1% target as a universal specification. The LC–MS identity guide helps separate identity evidence from a coincident peak.
Compare the right denominators
The NPY paper’s percentages use the preceding sample peak as denominator. For regulatory bioanalytical validation, ICH M10 instead specifies a blank after the highest calibrator and compares its analyte response with the LLOQ response (and internal-standard response separately). These are different tests; a 2% blank-to-high-standard ratio cannot be judged against the M10 threshold without the LLOQ signal. M10’s published thresholds are 20% of analyte response at LLOQ and 5% of internal-standard response in that context. They are not universal targets for non-regulatory research. [2, §3.2.6]
Before accepting a run, preserve the sequence: blank before high sample, high sample, first blank, later blanks and next low sample. Record both the blank/high ratio and blank/LLOQ ratio when a validated LLOQ exists. This keeps an apparently small percentage from hiding a large bias at the low end.
Evidence limit
This is a single NPY LC–MS setup, not a test of NHD lots or a general performance claim for all peptides. It is valuable for its experimental logic: isolate the source, repeat the blank sequence and verify the effect of each intervention. A laboratory should validate its own wash solvents for compatibility with the column, seals and mass-spectrometer source before implementation.
Primary source and claim trail
- Troubleshooting Carry-Over in the LC-MS Analysis of Biomolecules: The Case of Neuropeptide Y. Mass Spectrometry. 2020. DOI 10.5702/massspectrometry.S0083, PMID 33299733. Locations: Results and Discussion/Table 1 (1 µL, 1/5/10 µM, ratio definition and 4.05/0.36/0.47%); “Strategy for identifying carry-over sites,” Experiments 1–3 (needle and column isolation); Table 4 (post-seal-replacement blanks). Primary full text checked.
- International Council for Harmonisation. ICH M10: Bioanalytical Method Validation and Study Sample Analysis, final guideline, 2022. Location: §3.2.6 (carryover definition, blank after ULOQ, LLOQ and internal-standard denominators). Used only as a regulatory comparator, not to reinterpret the NPY experiment.
Sources & editorial method
AI-assisted editorial draft; independent Codex source, image and seven-language review; human professional review not claimed
2 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
This article summarizes third-party records and does not establish the identity, quality, safety or efficacy of any catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Troubleshooting Carry-Over in the LC-MS Analysis of Biomolecules: The Case of Neuropeptide YSource 1. Results and Discussion/Table 1 (1 µL, 1/5/10 µM, ratio definition and 4.05/0.36/0.47%); “Strategy for identifying carry-over sites,” Experiments 1–3 (needle and column isolation); Table 4 (post-seal-replacement blanks).
- International Council for Harmonisation. ICH M10: Bioanalytical Method Validation and Study Sample Analysis, final guideline, 2022. Location: §3.2.6 (carryover definition, blank after ULOQ, LLOQ and internal-standard denSource 2. §3.2.6 (carryover definition, blank after ULOQ, LLOQ and internal-standard denominators). Used only as a regulatory comparator, not to reinterpret the NPY experiment.
